These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 26413494)
21. Caregiver report versus clinician impression: disagreements in rating neuropsychiatric symptoms in Alzheimer's disease patients. Stella F; Forlenza OV; Laks J; de Andrade LP; de Castilho Cação J; Govone JS; de Medeiros K; Lyketsos CG Int J Geriatr Psychiatry; 2015 Dec; 30(12):1230-7. PubMed ID: 25754669 [TBL] [Abstract][Full Text] [Related]
22. Risperidone for psychosis-induced aggression or agitation (rapid tranquillisation). Ostinelli EG; Hussein M; Ahmed U; Rehman FU; Miramontes K; Adams CE Cochrane Database Syst Rev; 2018 Apr; 4(4):CD009412. PubMed ID: 29634083 [TBL] [Abstract][Full Text] [Related]
23. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Van Leeuwen E; Petrovic M; van Driel ML; De Sutter AI; Vander Stichele R; Declercq T; Christiaens T Cochrane Database Syst Rev; 2018 Apr; 3(3):CD007726. PubMed ID: 29605970 [TBL] [Abstract][Full Text] [Related]
25. Investigating the safety and efficacy of nabilone for the treatment of agitation in patients with moderate-to-severe Alzheimer's disease: Study protocol for a cross-over randomized controlled trial. Ruthirakuhan MT; Herrmann N; Gallagher D; Andreazza AC; Kiss A; Verhoeff NPLG; Black SE; Lanctôt KL Contemp Clin Trials Commun; 2019 Sep; 15():100385. PubMed ID: 31338476 [TBL] [Abstract][Full Text] [Related]
26. Neuropsychiatric symptoms and functional status in Alzheimer's disease and vascular dementia patients. D'Onofrio G; Sancarlo D; Panza F; Copetti M; Cascavilla L; Paris F; Seripa D; Matera MG; Solfrizzi V; Pellegrini F; Pilotto A Curr Alzheimer Res; 2012 Jul; 9(6):759-71. PubMed ID: 22715983 [TBL] [Abstract][Full Text] [Related]
27. Emerging therapies for treatment of agitation, psychosis, or apathy in Alzheimer's disease. Wang HJ; Chinna-Meyyappan A; Feldman OJ; Lanctôt KL Expert Opin Emerg Drugs; 2024 Jun; ():1-15. PubMed ID: 38822731 [TBL] [Abstract][Full Text] [Related]
28. Changes in nursing burden following memantine for agitation and aggression in long-term care residents with moderate to severe Alzheimer's disease: an open-label pilot study. Herrmann N; Cappell J; Eryavec GM; Lanctôt KL CNS Drugs; 2011 May; 25(5):425-33. PubMed ID: 21476613 [TBL] [Abstract][Full Text] [Related]
29. EU/US/CTAD Task Force: Lessons Learned from Recent and Current Alzheimer's Prevention Trials. Aisen P; Touchon J; Amariglio R; Andrieu S; Bateman R; Breitner J; Donohue M; Dunn B; Doody R; Fox N; Gauthier S; Grundman M; Hendrix S; Ho C; Isaac M; Raman R; Rosenberg P; Schindler R; Schneider L; Sperling R; Tariot P; Welsh-Bohmer K; Weiner M; Vellas B J Prev Alzheimers Dis; 2017; 4(2):116-124. PubMed ID: 29186281 [TBL] [Abstract][Full Text] [Related]
30. A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. Brodaty H; Ames D; Snowdon J; Woodward M; Kirwan J; Clarnette R; Lee E; Lyons B; Grossman F J Clin Psychiatry; 2003 Feb; 64(2):134-43. PubMed ID: 12633121 [TBL] [Abstract][Full Text] [Related]
31. Pharmacological Management of Agitation and Aggression in Alzheimer's Disease: A Review of Current and Novel Treatments. Liu CS; Ruthirakuhan M; Chau SA; Herrmann N; Carvalho AF; Lanctôt KL Curr Alzheimer Res; 2016; 13(10):1134-44. PubMed ID: 27137221 [TBL] [Abstract][Full Text] [Related]
32. Psychosocial or clinico-demographic factors related to neuropsychiatric symptoms in patients with Alzheimer's disease needing interventional treatment: analysis of the CATIE-AD study. Nagata T; Nakajima S; Shinagawa S; Plitman E; Graff-Guerrero A; Mimura M; Nakayama K Int J Geriatr Psychiatry; 2017 Dec; 32(12):1264-1271. PubMed ID: 27714849 [TBL] [Abstract][Full Text] [Related]
33. Understanding neuropsychiatric symptoms in Alzheimer's disease: challenges and advances in diagnosis and treatment. Pless A; Ware D; Saggu S; Rehman H; Morgan J; Wang Q Front Neurosci; 2023; 17():1263771. PubMed ID: 37732300 [TBL] [Abstract][Full Text] [Related]
35. Cannabinoid as Beneficial Replacement Therapy for Psychotropics to Treat Neuropsychiatric Symptoms in Severe Alzheimer's Dementia: A Clinical Case Report. Defrancesco M; Hofer A Front Psychiatry; 2020; 11():413. PubMed ID: 32477187 [TBL] [Abstract][Full Text] [Related]
36. Advancements in the treatment of agitation in Alzheimer's disease. Antonsdottir IM; Smith J; Keltz M; Porsteinsson AP Expert Opin Pharmacother; 2015; 16(11):1649-56. PubMed ID: 26159445 [TBL] [Abstract][Full Text] [Related]
37. Neuropsychiatric Symptoms and Risk of Progression to Alzheimer's Disease Among Mild Cognitive Impairment Subjects. Dietlin S; Soto M; Kiyasova V; Pueyo M; de Mauleon A; Delrieu J; Ousset PJ; Vellas B J Alzheimers Dis; 2019; 70(1):25-34. PubMed ID: 31127783 [TBL] [Abstract][Full Text] [Related]